Clinical course of patients with hepatocellular carcinoma who experienced radiologic complete response after radioembolization

被引:0
|
作者
Moon, Sungmo [1 ]
Kim, Gyoung Min [1 ]
Won, Jong Yun [1 ]
Kwon, Joon Ho [1 ]
Park, Juil [1 ]
Han, Kichang [1 ]
Kim, Man-Deuk [1 ]
Kim, Hyung Cheol [1 ]
Kim, Dong Kyu [1 ]
Choi, Jin Young [1 ]
机构
[1] Yonsei Univ, Severance Hosp, Res Inst Radiol Sci, Dept Radiol,Coll Med, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
hepatocellular carcinoma; radioembolization; complete response; recurrence; predisposing factor; Y-90; RADIOEMBOLIZATION; SURVIVAL; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fonc.2024.1349632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The purpose of this study is to elucidate the patterns of recurrence of hepatocellular carcinoma and to analyze factors that can predict recurrence after complete response to radioembolization.Materials and methods A total of 289 consecutive patients who underwent radioembolization for the treatment of hepatocellular carcinoma at a single tertiary center were retrospectively reviewed. Baseline characteristics were collected and compared between the group showing complete response and the group showing noncomplete response. Data on recurrence status, time to recurrence, and the patterns of recurrence among the patients who showed radiologic complete response were collected. The group that maintained complete response and the group that experienced recurrence were compared, and the risk factors affecting recurrence were evaluated by logistic regression analysis.Results The complete response rate was 24.9% (73/289). Age, sex, tumor markers, maximum tumor diameter, multiplicity, presence of vascular invasion, and target radiation dose were significantly different between the complete response and noncomplete response groups. The recurrence rate after complete response was 38.4% (28/73), and 67.9% (19/28) of recurrences occurred by 8 months after complete response. Eight patients who underwent resection/transplantation after complete response experienced no recurrence. Multiple tumors and a lower target radiation dose were independent risk factors of recurrence after complete response in the multivariate logistic regression.Conclusion Hepatocellular carcinoma recurrence following complete response after radioembolization is not uncommon and frequently occurs within 1 year after complete response. Multiple tumors and a lower target radiation dose may be risk factors for recurrence.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Durable complete response of hepatocellular carcinoma after metronomic capecitabine
    Brandi, Giovanni
    de Rosa, Francesco
    Bolondi, Luigi
    Agostini, Valentina
    Di Girolamo, Stefania
    Nobili, Elisabetta
    Biasco, Guido
    TUMORI, 2010, 96 (06) : 1028 - 1030
  • [32] Clinical Complete Response After Conversion Therapy for Unresectable Hepatocellular Carcinoma: Is Salvage Hepatectomy Necessary?
    Wu, Jia-Yi
    Wu, Jun-Yi
    Liu, De-Yi
    Li, Han
    Zhuang, Shao-Wu
    Li, Bin
    Zhou, Jian-Yin
    Huang, Jing-Yao
    Zhang, Zhi-Bo
    Li, Shu-Qun
    Yan, Mao-Lin
    Wang, Yao-Dong
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 2161 - 2171
  • [33] Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response
    Kim, Hyo-Cheol
    Choi, Jin Woo
    Lee, Myungsu
    Kim, Yoon Jun
    Paeng, Jin Chul
    Chung, Jin Wook
    ANTICANCER RESEARCH, 2021, 41 (05) : 2625 - 2635
  • [34] Yttrium-90 radioembolization in patients with hepatocellular carcinoma who have previously received sorafenib
    Rana, Nitesh
    Ju, Andrew Wenhua
    Bazylewicz, Michael
    Kallakury, Bhaskar
    He, Aiwu Ruth
    Unger, Keith R.
    Lee, Justin S.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [35] KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
    Vogel, A.
    Zhu, A. X.
    Cheng, A-L.
    Yau, T.
    Zhou, J.
    Kim, E.
    Malhotra, U.
    Siegel, A. B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S703 - S703
  • [36] Systemic therapy with lenvatinib in advanced hepatocellular carcinoma: what to do in the case of a complete radiologic response?
    Shah, Nikita C.
    Shah, Harsh C.
    Amarapurkar, Anjali D.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (01) : 118 - 119
  • [37] Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization
    Lorenzin, Dario
    Pravisani, Riccardo
    Leo, Cosimo Alex
    Bugiantella, Walter
    Soardo, Giorgio
    Carnelutti, Alessia
    Umberto, Baccarani
    Risaliti, Andrea
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (02) : 65 - 69
  • [38] Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When... and Y(90)?
    Mehta, Neil
    Yao, Francis Y.
    GASTROENTEROLOGY, 2016, 151 (06) : 1062 - 1065
  • [39] Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses
    Crisanta H. Ilagan
    Debra A. Goldman
    Mithat Gönen
    Victoria G. Aveson
    Michelle Babicky
    Vinod P. Balachandran
    Jeffrey A. Drebin
    William R. Jarnagin
    Alice C. Wei
    T. Peter Kingham
    Ghassan K. Abou-Alfa
    Karen T. Brown
    Michael I. D’Angelica
    Annals of Surgical Oncology, 2022, 29 : 6815 - 6826
  • [40] Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses
    Ilagan, Crisanta H.
    Goldman, Debra A.
    Gonen, Mithat
    Aveson, Victoria G.
    Babicky, Michelle
    Balachandran, Vinod P.
    Drebin, Jeffrey A.
    Jarnagin, William R.
    Wei, Alice C.
    Kingham, T. Peter
    Abou-Alfa, Ghassan K.
    Brown, Karen T.
    D'Angelica, Michael, I
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (11) : 6815 - 6826